TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05749640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Precontoured sectional matrix EZ COAT
Description: All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PerForm™
Description: Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AdDent Trimax™
Description: Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact Pro™
Description: Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
Study: NCT06431425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCG Family Clinic
Description: The DNA-poli is an online tool which is designed as an addition to the current genetic counseling method to make the process more efficient and to increase the uptake without compromising counseling quality. Probands can invite their at-risk family members by entering their email addresses. The family members are invited to the DNA-poli via which they can get all the information needed to make a well-considered decision about genetic testing. The information is provided in different formats, for example via a virtual assistant and via videos, which they can evaluate at their own pace, and which can be reread or rewatched. Afterwards they can request an appointment with a health care professional and make a definite decision about genetic testing.
Study: NCT05115435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuro linguistic programming
Description: Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
Study: NCT05753462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1, SQY51
Description: SQY51 is administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 1)
Description: SQY51 is administered by intravenous infusion at dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 2)
Description: SQY51 is administered by intravenous infusion at dose 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2a, SQY51 (cohort 3)
Description: SQY51 is administered by intravenous infusion at dose 3.
Study: NCT05981326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Centralized blood samples will be performed at inclusion + evaluation visits

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Centralized blood samples will be performed at inclusion + evaluation visits

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Centralized blood samples will be performed at inclusion + evaluation visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
Study: NCT06546891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Rowing
Description: 12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
Study: NCT04965376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral joint steroid injection
Description: Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block steroid injection
Description: Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
Study: NCT06546475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: regular dose or high dose add-on

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: regular dose or high dose add-on
Study: NCT06414044

Intervention type: DRUG
Intervention: Atogepant 60 mg
Description: Patients using atogepant 60 mg tablet daily as migraine prevention

Intervention type: DRUG
Intervention: Atogepant 60 mg
Description: Patients using atogepant 60 mg tablet daily as migraine prevention
Study: NCT05200312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg capsules administered by mouth twice daily (21-day cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT05100069

Intervention type: DRUG
Intervention: Brigatinib
Description: Brigatinib Tablets
Study: NCT05200312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (or equivalent)
Description: 40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study: NCT04787003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oncolytic virus (OVV-01) injection
Description: intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
Study: NCT06070116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin w/ Albendazole
Description: Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin + Diethylcarbamazine + Albendazole
Description: Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin + Albendazole
Description: Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin + Diethylcarbamazine + Albendazole
Description: Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
Study: NCT06460597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papworth Technique
Description: The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
Study: NCT06457399

Intervention type: DRUG
Intervention: Heliox
Description: Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.

Intervention type: DRUG
Intervention: Oxygen
Description: Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
Study: NCT06460597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama
Description: Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
Study: NCT05308758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-based High-Intensity Interval Training
Description: There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GameSAE
Description: Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
Study: NCT04940130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sanaria® PfSPZ Vaccine
Description: non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
Study: NCT05224154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinent Contingent (AC) Re-Connect
Description: Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Submission Contingent (SC) Re-Connect
Description: Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
Study: NCT06071637

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double low-power laser therapy simultaneous applicated
Description: Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double low-power laser therapy simultaneous applicated
Description: Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
Study: NCT06299579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD-11 for injection test group
Description: The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control group
Description: The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
Study: NCT04928495

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C 500 mg / day for ten days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: N-acetylcysteine 1800 mg / day for ten days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC + Bromhexine (BMX)
Description: NAC + Bromhexine (BMX) 32 mg / day for ten days.
Study: NCT04940130

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo control- saline
Study: NCT05191355

Intervention type: BIOLOGICAL
Intervention: blood test
Description: Blood spot collection for sampling

Intervention type: BIOLOGICAL
Intervention: blood test
Description: Blood spot collection for sampling
Study: NCT04495686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered Care Coordination Program
Description: Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered Care Coordination Program
Description: Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform.
Study: NCT04731623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION904
Description: ION904 will be administered by SC injection.
Study: NCT04299386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoPhylaxis
Description: NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImplanTreat
Description: ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
Study: NCT01953211

Intervention type: DRUG
Intervention: combined oral contraceptives
Study: NCT04731623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sterile saline) will be administered by SC injection.
Study: NCT06355401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20mg
Description: maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
Study: NCT06418334

Intervention type: DIAGNOSTIC_TEST
Intervention: Thoracal hyperkyphosis study form
Description: Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.

Intervention type: DIAGNOSTIC_TEST
Intervention: Scoliosis graphy
Description: Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic Measurement
Description: Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
Study: NCT05305820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
Study: NCT06251869

Intervention type: PROCEDURE
Intervention: total hip arthroplasty with electrocoagulation
Description: using normal technique

Intervention type: PROCEDURE
Intervention: total hip arthroplasty without electrocoagulation
Description: using only scalpel and pean as hemostasis and incision

Intervention type: PROCEDURE
Intervention: total knee arthroplasty with electrocoagulation
Description: using normal technique

Intervention type: PROCEDURE
Intervention: total knee arthroplasty without electrocoagulation
Description: using only scalpel and pean as hemostasis and incision
Study: NCT04742920

Intervention type: DEVICE
Group type: OTHER
Intervention: Middle Meningeal Artery Embolization
Description: MMA embolization using the Onyx™ non-adhesive liquid embolic agent within 72 hours after randomization in addition to standard management

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Management
Description: Procedure : Surgical Management Surgical evacuation of the subdural hematoma~Other: Conservative Management Standard medical management: drug treatment and/or observation
Study: NCT05057143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implants
Description: 3D printed implants

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates
Description: Titanium plates
Study: NCT06168370

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT guided strategy
Description: 1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT.
Study: NCT06114004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor 20 MG
Description: After having completed the Phase I part, the recommended dose for Phase II is 60mg Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at the dose 1200 mg/m2 (10 mg/m2/min) days 1 and 8 every 21 days.
Study: NCT05371067

Intervention type: OTHER
Group type: OTHER
Intervention: Fructose respiratory test
Description: Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
Study: NCT05085431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions CD19/BCMA CAR T-cells
Description: Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
Study: NCT05291416

Intervention type: DIAGNOSTIC_TEST
Intervention: densitometry/ handgrip dynamometer
Description: all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer

Intervention type: DIAGNOSTIC_TEST
Intervention: densitometry/ handgrip dynamometer
Description: all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
Study: NCT04884295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XVR011
Description: Single dose of XVR011 via intravenous (IV) infusion